Clinical trials
Systemic Amyloidosis clinical trials
Below are recruiting systemic amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 19 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06292780RecruitingPhase 1/Phase 2
Testing linvoseltamab for AL amyloidosis that came back
This trial tests a new drug called linvoseltamab for people with AL amyloidosis that has returned or is not responding to treatment. It aims to see if the drug is safe and helps control the disease.
Duarte, CaliforniaAges 18 years+ - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT07689331Recruiting
Hungarian national amyloidosis study
This study creates a registry for people diagnosed with systemic amyloidosis in Hungary. It helps doctors better understand the condition by collecting medical history and tracking outcomes over time.
BalatonfüredAges 18 years+ - NCT06342466RecruitingPhase 2
Study of bortezomib, pomalidomide, and dexamethasone for AL amyloidosis
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Beijing, Beijing MunicipalityAges 18–90 - NCT07626476RecruitingEarly Phase 1
CAR-T Cell Therapy for Advanced Light Chain Amyloidosis
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
Beijing, Fengtai DistrictAges 18 years+ - NCT06887283Recruiting
Essen Amyloidosis Registry Study
This study collects information from people with suspected or confirmed amyloidosis. The goal is to learn more about the condition and improve patient care.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT07266116RecruitingPhase 1/Phase 2
TQB2934 injection for light chain amyloidosis
This trial tests a new injectable drug called TQB2934 for people with systemic light chain amyloidosis. It aims to see if the drug is safe and effective for those whose disease has come back or gotten worse after previous treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT05758493RecruitingPhase 2
Iodine-124 scan study for systemic amyloidosis
This Phase 2 study tests an iodine-based scan medicine to help learn how systemic amyloidosis affects the body and organs. It may help doctors better characterize the disease using specific imaging tests.
Portland, OregonAges 40–90 - NCT06803082Recruiting
How systemic light chain amyloidosis affects the eyes
This study looks at how systemic light chain amyloidosis, a condition where abnormal proteins build up in organs, may affect your eyes. By comparing eye exams of people with and without the disease, researchers hope to learn more about eye-related changes so they can improve care.
Guangzhou, GuangdongAges 18–80 - NCT06192979Recruiting
First-line treatment for AL amyloidosis with t(11;14)
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
Beijing, Beijing MunicipalityAges Any age - NCT06627309Recruiting
Rapid blood protein response and remission in AL amyloidosis
This trial is for people with AL amyloidosis who are being treated with daratumumab, bortezomib, and dexamethasone. It looks at how quickly a certain blood protein (called dFLC) drops after treatment starts and whether that predicts a complete remission.
Beijing, Beijing MunicipalityAges 18–99 - NCT07151690RecruitingPhase 2
BCMA/CD3 bispecific antibody for newly diagnosed AL amyloidosis
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
TianjinAges 18 years+ - NCT06672237RecruitingPhase 3
Study of NTLA-2001 for hereditary ATTR amyloidosis with nerve damage
This study is testing a new gene-silencing treatment called NTLA-2001 for people with hereditary ATTR amyloidosis that causes nerve damage. It works by stopping the body from making a faulty protein that builds up and harms nerves.
Buenos AiresAges 18–85 - NCT06699394Recruiting
Teclistamab for AL amyloidosis after standard therapy
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
Beijing, Beijing MunicipalityAges Any age - NCT07388602RecruitingPhase 3
New drug combo for newly diagnosed AL amyloidosis
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06866912Recruiting
Observational study of amyloidosis and TTR gene carriers
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
BolognaAges 18–99 - NCT05978661RecruitingPhase 1
FKC288 cell therapy for AL amyloidosis
This trial tests a new cell therapy called FKC288 for people with AL amyloidosis that hasn't been helped by standard treatments. The goal is to see if it can safely control the disease and improve organ function.
Nanjing, JiangsuAges 18–70 - NCT07124377Recruiting
Study of hereditary ATTR amyloidosis symptoms
This study looks at how a specific genetic change (Val50Met) affects people with hereditary ATTR amyloidosis. It may help doctors better understand the condition and its symptoms.
Charata, Chaco ProvinceAges 20 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+
Hear when a new Systemic Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic amyloidosis?
- Yes. Clin2 currently lists 19 recruiting systemic amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.